Compare · ARTV vs MRNA
ARTV vs MRNA
Side-by-side comparison of Artiva Biotherapeutics Inc. (ARTV) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARTV and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $20.12B, about 78.9x ARTV ($255.1M).
- Over the past year, ARTV is up 323.8% and MRNA is up 84.6% - ARTV leads by 239.1 points.
- MRNA has been more active in the news (8 items in the past 4 weeks vs 1 for ARTV).
- MRNA has more recent analyst coverage (25 ratings vs 7 for ARTV).
- Company
- Artiva Biotherapeutics Inc.
- Moderna Inc.
- Price
- $10.34-8.29%
- $50.74-3.98%
- Market cap
- $255.1M
- $20.12B
- 1M return
- +88.00%
- -5.22%
- 1Y return
- +323.77%
- +84.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2018
- News (4w)
- 1
- 8
- Recent ratings
- 7
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ARTV
- Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
- Chief Financial Officer Huston Thad Allen was granted 220,000 shares (SEC Form 4)
- SEC Form S-8 filed by Artiva Biotherapeutics Inc.
- SEC Form 10-K filed by Artiva Biotherapeutics Inc.
- Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
- Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
- SEC Form 3 filed by new insider Huston Thad Allen
- SEC Form 8-K filed by Artiva Biotherapeutics Inc.
- Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
Latest MRNA
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
- Moderna to Present at Upcoming Conferences in May 2026
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
- SEC Form 4 filed by Mock James M
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- SEC Form DEF 14A filed by Moderna Inc.